Want to see FR:ALIMP full AI Analyst Report?
ALIMP Stock Chart & Stats
€0.26
<€0.01(1.57%)
At close: 4:00 PM EST
€0.26
<€0.01(1.57%)
Day’s Range― - ―
52-Week Range€0.14 - €0.44
Previous CloseN/A
Volume2.90K
Average Volume (3M)332.66K
Market Cap
€24.16M
Enterprise Value€28.91
Total Cash (Recent Filing)€3.01M
Total Debt (Recent Filing)€5.92M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Sep 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding143,818,970
10 Day Avg. Volume485,065
30 Day Avg. Volume332,657
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)70.59
Price to Sales (P/S)2.29
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue RecoveryA three-year top-line rebound to €12.47M demonstrates durable demand traction for Implanet's implant systems. Sustained revenue growth widens the opportunity to scale distribution, amortize fixed R&D and SG&A, and create a clearer runway toward operating leverage if the trend persists.
Improving Gross MarginsA roughly 11-point gross margin improvement signals stronger product mix, pricing or manufacturing efficiency. Higher gross margins are structurally important: they increase the portion of revenue available to cover R&D and SG&A, improving the probability of eventual operating profitability.
Repeatable Consumable Revenue ModelImplanet's implant platforms create recurring revenue from consumables and compatible follow-on components. Platform-driven repeat purchasing by hospitals and surgeons supports predictable procedure-linked demand and provides a structural base for cross-sell and incremental lifetime customer value.
Bears Say
Persistent Net LossesDespite revenue and margin gains, Implanet remains materially loss-making. Continued negative net income indicates the business has not yet converted top-line progress into sustainable earnings, requiring prolonged cost control or higher margins to reach self-sustaining profitability.
Very Thin Equity And High LeverageA capital structure with minimal equity and elevated debt creates limited buffer against further losses or unexpected shocks. High leverage raises refinancing and interest risks, constrains strategic flexibility, and increases the chance external funding will be required under adverse conditions.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow means Implanet currently relies on external financing to fund operations and growth. Until operating cash flow turns sustainably positive, the company faces funding risk, potential dilution or higher financing costs that can hamper long-term execution.
ALIMP FAQ
What was Implanet SA’s price range in the past 12 months?
Implanet SA lowest stock price was €0.14 and its highest was €0.44 in the past 12 months.
What is Implanet SA’s market cap?
Implanet SA’s market cap is €24.16M.
When is Implanet SA’s upcoming earnings report date?
Implanet SA’s upcoming earnings report date is Sep 15, 2026 which is in 48 days.
How were Implanet SA’s earnings last quarter?
Implanet SA released its earnings results on Feb 24, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Implanet SA overvalued?
According to Wall Street analysts Implanet SA’s price is currently Overvalued.
Does Implanet SA pay dividends?
Implanet SA does not currently pay dividends.
What is Implanet SA’s EPS estimate?
Implanet SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Implanet SA have?
Implanet SA has 143,818,970 shares outstanding.
What happened to Implanet SA’s price movement after its last earnings report?
Implanet SA reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.162%.
Which hedge fund is a major shareholder of Implanet SA?
Currently, no hedge funds are holding shares in FR:ALIMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Implanet SA
Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Diagnostic Medical Systems
―
Median Technologies
―
Affluent Medical SA
―